Basilea Pharmaceutica - BARDA backs Basilea’s anti-infectives programme
Basilea has bagged a multi-year agreement with the Biomedical Advanced Research and Development Authority (BARDA), potentially worth US$268m, to...
284 Views
Basilea Pharmaceutica - H2 rewards continue: US$25m Cresemba milestone
H224 continues to be a rewarding period for Basilea Pharmaceutica, with the announcement of a third successive milestone payment for Cresemba in...
323 Views
Basilea Pharmaceutica - EU paediatric approval triggers CHF10m milestone
Basilea has announced yet another milestone following the European Commission (EC) approval for Cresemba’s use in the paediatric population (in...
221 Views
Basilea Pharmaceutica - Another Cresemba milestone payment in the bank
The uptrend in Cresemba sales in Asia-Pacific and China triggered the receipt of Basilea’s third milestone payment of US$1.25m from Pfizer for the...
296 Views
Basilea Pharmaceutica - Poised for an eventful H224
Basilea’s H124 results reflect strong momentum across its pipeline and we expect the pace to accelerate in H224. The key highlight of the period...
296 Views